Table 2

Characteristics of children started on antiretroviral treatment (n = 315)

Age at starta

7.2 (4.5 – 10.4)

< 3 yearsb

38 (12%)

3 – 4.9 yearsb

51 (16%)

5 – 14.9 yearsb

226 (72%)

Sex (male/female)b

157/158 (50/50%)

Clinical WHO-stageqb

WHO stage I

43 (13.7%)

WHO stage II

145 (46.0%)

WHO stage III

115 (36.5%)

WHO stage IV

12 (3.8%)

Weight for age (Z-score) (n = 293)a

-1.9 (-3.0;-0.9)

Baseline CD4 count % (n = 282)a

14 (9–18)

< 15%b

158 (56.0%)

15–25%b

118 (41.8%)

> 25%b

6 (2.1%)

Baseline absolute CD4 counts (n= 302)a

345 (229–572)

Baseline hemoglobin (mg/dl)(n = 268)a

11.0 (10.3–11.8)

ART regimenb

d4T/3TC/NVP

281 (89.2%)

d4T/3TC/EFV

6 (1.9%)

AZT/3TC/NVP

19 (6.0%)

AZT/3TC/EFV

9 (2.9%)

Time on ART (years)c

2.0 (1.2–2.6)

Total patient years of follow-up

598

On tablets (FDC)

577

On syrup

21

< 1 year vs. ≥ 1 yearb

59 (19 %) vs 256 (81 %)


a Values are expressed as median (interquartile range)

b Values are expressed as n (%)

c As of June 30/2007 (closing date of dataset)

WHO: world health organization; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; FDC: fixed-dose combination

van Griensven et al. BMC Pediatrics 2008 8:39   doi:10.1186/1471-2431-8-39

Open Data